We're pleased to share our latest paper, published in Drug and Drug candidates titled "Probing Redox Responses and DNA Interactions in Drug Discovery"

@istanbulluh.bsky.social
@huseyinkosker.bsky.social

Our project entitled ‘Synthesis and biological activities of antimycobacterial effective pyrrolamide derivatives’has been entitled to support within the scope of TÜBİTAK 2209-A Research Projects Support Programme for Undergraduate Students 2024/1
@istanbulluh.bsky.social
@huseyinkosker.bsky.social

We're excited to share our latest paper, published in ChemBiodiv titled ‘Novel Triazolopyrimidinone Compounds as Adipocyte Fatty Acid Binding Protein (FABP4) Inhibitors’
doi.org/10.1002/cbdv...

@istanbulluh.bsky.social
@huseyinkosker.bsky.social

Our project, submitted to the TUBITAK-2515 programme within the COST-CA21111 action "One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthDrugs)", was eligible for funding.
@istanbulluh.bsky.social
@huseyinkosker.bsky.social

Within the scope of TÜBİTAK-1001-2024-2; our project entitled "Synthesis of new thiazolopyrimidine pyrrolimide derivatives as DNA GyraseB inhibitor antibacterial agents and evaluation of their biological activities" was found eligible for support
@istanbulluh.bsky.social
@huseyinkosker.bsky.social

@istanbulluh.bsky.social

I am pleased to announce that our groups latest paper is entitled:“ Biological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms” has been published in European Journal of MedChem. @istanbulluh.bsky.social